Dr. Clay Siegall is the founder and current CEO of Seattle Genetics, a biotech firm. It specializes in developing targeted therapy drugs for a variety of diseases that have not shown improvement over the years. Clay has led the company to greatness since it was established in 1988. He has contributed to the development of an antibody drug conjugate that has been approved by FDA. Clay has developed a strong pipeline of over 20 drugs and a connection of strategic partnership with prestigious drug manufacturers, including Pfizer and Bayer. He is also an academic scholar with a degree in zoology from the University of Maryland. Clay studied at George Washington University where he earned his Ph. D in genetics.
Clay’s leadership, alongside his crew of researchers, has played a great role in the cancer research space. The company is positioned to shift to the 21st-century drug development with authority following the evolution of Seattle Genetics’s drug list and the progressive increase in the company’s drug portfolio. Further, Clay believes that the systemic chemotherapies for treating cancer should be replaced with effective targeted drugs.
A Summary of the Interview
Clay cited that he was inspired to begin his business when he became interested in cancer treatment. He was also interested in medicine and the power of technology. Clay Siegall mentioned that the company makes money through selling their FDA approved drugs. He added that the company became profitable after the IPO ten years ago.
Clay said that Seattle Genetics experienced a tough moment when they depleted their operating capital reserves, in 1999 and 2000, but managed to pull through that ordeal. He mentioned that the company’s sale staffs play a crucial role in attracting customers. Clay added that the company spends time in wining, dining, and negotiating with potential clients to generate new businesses. He cited that hard work helps him to be a successful man.
Clay who is the current CEO of the Seattle-based biotech firm, Seattle Genetics, previously worked at a Pharmaceutical Research Institute called Bristol-Myers Squibb from 1991 to 1997. He also worked at the National Cancer Institute from 1988 to 1991.
Clay is a member of the boards of directors of Alder Biopharmaceuticals, Ultragenynx Pharmaceutical, and Washington Roundtable. He is a prominent author of over 70 publications. Clay also holds 15 patents and several awards.